[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100493312":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":105,"collaborators":10,"id":107,"slug":108,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":10,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":10,"studyType":120,"phases":10,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Capmatinib",null,"Participants will be treated with capmatinib as per locally approved label",[13],"Other: Capmatinib",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"OTHER","There is no treatment allocation. Capmatinib will be prescribed by the physician as per locally approved label. Treatment duration depends on the decision of treating physician. No drug will be dispensed from Novartis",[9],[20],"Tabrecta",[22],{"name":23,"affiliation":23,"role":24},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":23,"role":27,"phone":10,"phoneExt":10,"email":10},[32,45,54,63,71,76,84,92,95,100],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":10,"cosmosGeoPoint":39,"geoPoint":44,"contacts":10},"Novartis Investigative Site","RECRUITING","Daegu","Dalseo gu","42602","South Korea",{"type":40,"coordinates":41},"Point",[42,43],128.59111,35.87028,{"lat":43,"lon":42},{"facility":33,"status":34,"city":46,"state":47,"zip":48,"country":38,"countryCode":10,"cosmosGeoPoint":49,"geoPoint":53,"contacts":10},"Suwon","Gyeonggi-do","16499",{"type":40,"coordinates":50},[51,52],127.00889,37.29111,{"lat":52,"lon":51},{"facility":33,"status":34,"city":55,"state":56,"zip":57,"country":38,"countryCode":10,"cosmosGeoPoint":58,"geoPoint":62,"contacts":10},"Incheon","Korea","405 760",{"type":40,"coordinates":59},[60,61],126.70515,37.45646,{"lat":61,"lon":60},{"facility":33,"status":34,"city":64,"state":56,"zip":65,"country":38,"countryCode":10,"cosmosGeoPoint":66,"geoPoint":70,"contacts":10},"Seoul","02447",{"type":40,"coordinates":67},[68,69],126.9784,37.566,{"lat":69,"lon":68},{"facility":33,"status":34,"city":64,"state":64,"zip":72,"country":38,"countryCode":10,"cosmosGeoPoint":73,"geoPoint":75,"contacts":10},"06351",{"type":40,"coordinates":74},[68,69],{"lat":69,"lon":68},{"facility":33,"status":34,"city":77,"state":10,"zip":78,"country":38,"countryCode":10,"cosmosGeoPoint":79,"geoPoint":83,"contacts":10},"Busan","602-030",{"type":40,"coordinates":80},[81,82],129.03004,35.10168,{"lat":82,"lon":81},{"facility":33,"status":34,"city":85,"state":10,"zip":86,"country":38,"countryCode":10,"cosmosGeoPoint":87,"geoPoint":91,"contacts":10},"Daejeon","302-241",{"type":40,"coordinates":88},[89,90],127.38493,36.34913,{"lat":90,"lon":89},{"facility":33,"status":34,"city":93,"state":10,"zip":94,"country":38,"countryCode":10,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Jeollanam","519763",{"facility":33,"status":34,"city":64,"state":10,"zip":96,"country":38,"countryCode":10,"cosmosGeoPoint":97,"geoPoint":99,"contacts":10},"05505",{"type":40,"coordinates":98},[68,69],{"lat":69,"lon":68},{"facility":33,"status":34,"city":64,"state":10,"zip":101,"country":38,"countryCode":10,"cosmosGeoPoint":102,"geoPoint":104,"contacts":10},"06591",{"type":40,"coordinates":103},[68,69],{"lat":69,"lon":68},{"type":106,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100493312","a-post-approval-commitment-study-on-tabrecta-capmatinib-in-south-korea-100493312",false,"NCT05703516","A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea","A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea; Open Label, Prospective, Multicenter, Post Approval Surveillance","Inclusion Criteria:\n\n* Signed informed consent must be obtained prior to participation in the study.\n* Subject who are diagnosed as exon 14 skipping mutated NSCLC from tissue or plasma(ctDNA) sample analysis by treating physician (i.e. Any kind of diagnostic methods the institution currently has. Diagnostic modalities for research purpose would be also allowable.)\n* Subject who plan to receive Tabrecta® (Capmatinib) as per locally approved label\n\nExclusion Criteria:\n\n* Subject with contraindication according to the locally approved label\n* Subject whose medical record is not accessible\n* Subject who are not willing to provide informed consent","ALL","18 Years","100 Years",{"count":118,"type":119},44,"ESTIMATED","OBSERVATIONAL","This is an open label, prospective, multicenter, non-comparative study to assess the safety and effectiveness of Tabrecta® (Capmatinib) in real world setting. Also, this study is to fulfill the regulatory requirements as part of the RMP (Risk Management Plan) for Tabrecta® (Capmatinib), as requested by Korea Health Authority, MFDS (Ministry of Food and Drug Safety).",[123],"Non-Small-Cell Lung Carcinoma",[125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144],"Non Small Cell Lung","Non Small Cell Lung Cancer","Non-small cell lung cancer","NSCLC","INC280","Non-small cell lung carcinoma (NSCLC)","lung cancer","lung adenocarcinoma","Non small cell lung carcinoma","MET exon 14 deletion","METex14del","MET exon 14 skipping","MET exon 14 mutation","MET mutation","MET amplification","MET inhibitor","MET dysregulation","MET activation","MET signaling","MET pathway","2026-05-28",{"date":147,"type":148},"2026-06-01","ACTUAL",{"date":150,"type":148},"2023-06-12",{"date":152,"type":119},"2026-10-31",{"name":23,"class":6},10]